<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2015031521469N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2015-06-03</date_registration>
      <primary_sponsor>Vice chancellor for research, Shiraz University of Medical Science</primary_sponsor>
      <public_title>Efficacy of Nepeta Menthoides in depression</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the efficacy of Nepeta mentoithes Boiss &amp; Bohse and a common anti depressant drug (Sertraline) in mild to moderate major depression</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-04-07</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/18805</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Randomization: Blocked randomization; Blinding with use of  Sertraline in the same capsules for control group, all capsules are similar in size and colour,  boxes in which capsules pack have the same shape in both groups. Patients and researcher who evaluate study out comes and even though the data analyzer are blind and do not know which group receives Sertraline or Nepeta .</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Depression. Condition 2: Anxiety.</hc_freetext>
      <i_freetext>Intervention 1: One 400 mg oral capsule from Nepeta menthoides aerial parts freeze-dried water extract (extract concentration, 10%), twice daily (one in morning half hour before breakfast  and one at night 1-2 hour before usual sleep time) for one month. Intervention 2: Serteraline (Sertrabiol manufactured by Bakhtar Bioshimi Co.)                                                   , 50 mg in each capsule, one capsule twice daily.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sepideh Koloury</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Traditional Persian Medicine college,  School of Medicine,  Imam Hossein Sq., Zand St., Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7194647989</zip>
        <telephone>+98 71 3233 7589</telephone>
        <email>kolouri@sums.ac.ir, sepidehkolouri@yahoo.com</email>
        <affiliation>Shiraz University of Medical Science</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Firoozabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz Department of psychiatry, Hafez hospital, Chamran Blvd., Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71946-34786</zip>
        <telephone>+98 71 3627 9319</telephone>
        <email>firooza@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Science</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Adult outpatients between 18-65 referring to psychiatry clinic of Shiraz medical university; meet Becks depression inventory (BDI-II) and DSM-V-TR criteria for mild to moderate major depression; confirmation of the diagnosis by at least two psychiatrist; and  informed consent.&#13;
Exclusion criteria:  Having other conditions assuming depression such as: hypothyroidism, psychiatric disorders except for mild to moderate  major depression, mental disorders i.e. dementia&#13;
 or mental retardation; allergy to Nepeta Menthoides or other mentheae family (Lamiaceaes);  substance dependency; pregnancy; suicidal thinking or needing to electroconvulsive therapy; not having informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F32.0, F32</hc_code>
      <hc_code>F41</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Mild depressive episode, moderate depressive episode, recurrent depressive disorder current episode mild, recurrent depressive disorder current episode moderate</hc_keyword>
      <hc_keyword>Other anxiety disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>One 400 mg oral capsule from Nepeta menthoides aerial parts freeze-dried water extract (extract concentration, 10%), twice daily (one in morning half hour before breakfast  and one at night 1-2 hour before usual sleep time) for one month</i_keyword>
      <i_keyword>Serteraline (Sertrabiol manufactured by Bakhtar Bioshimi Co.)                                                   , 50 mg in each capsule, one capsule twice daily</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of depression. Timepoint: At the base line,2nd week, 4th week after beginning of intervention and then in 6th week (2 weeks after the end of intervention). Method of measurement: Beck depression inventory(BDI-II) score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Side effects profile. Timepoint: At the base line, 2nd week, 4th week after beginning of intervention and then in 6th week (2 weeks after the end of intervention). Method of measurement: Clinical interview and physical examination and  list in a table.</sec_outcome>
      <sec_outcome>Severity of anxiety. Timepoint: At the base line, 2nd week, 4th week after beginning of intervention and then in6th week (2 weeks after the end of intervention). Method of measurement: Beck anxiety inventory (BAI) score.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id>CT- 9470 - 7440</sec_id>
        <issuing_authority>Iranian Registry of Clinical Trial</issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Shiraz University of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-04-07</approval_date>
        <contact_name>Ethic committee of Shiraz University of Medical Science</contact_name>
        <contact_address>Vice chancellor for research and technology office, Shiraz University of Medical Science, Zand street,Shiraz Shiraz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
